In the health industry, courage should be measured by what companies reveal—not what they hide. Too often it’s the reverse: labels skim the details, marketing leans on broad promises, and supply chains vanish behind jargon. That’s why the story of kratom and 7-hydroxymitragynine (7-OH) matters—not only for consumers trying to understand the difference, but for an industry grappling with truth, trust, and accountability.
The Distinction Matters
Kratom, a Southeast Asian botanical leaf, contains fifty-two distinct alkaloids that together shape its effects. Its use spans centuries, rooted in the routines of workers who relied on it for stamina, pain relief, and resilience. Among those alkaloids is 7-OH, which in the natural leaf appears only in trace amounts, forming slowly as the plant oxidizes and breaks down.
The problem isn’t the plant; it’s the manipulation. In recent years, some manufacturers have chemically enriched products with concentrated 7-OH, creating substances far more potent than anything found in the leaf. Unlike mitragynine—kratom’s primary alkaloid and a partial agonist—synthetic 7-OH engages opioid receptors with far higher efficacy, magnifying risk and mimicking the profile of the most dangerous pharmaceuticals.
That distinction should anchor every conversation. Yet in the rush for headlines, many outlets blur the lines, branding kratom “gas-station heroin” and leaving clinicians and patients to navigate a distorted narrative.
What the FDA Study Shows
A recent FDA-funded pilot study led by researcher Chad Reissig, PhD, offers one of the clearest snapshots yet of how botanical kratom behaves in a controlled clinical setting. Forty participants received encapsulated ground kratom leaf powder in doses ranging from one to twelve grams, with results that complicate the narrative often painted in headlines.
The study found that “no serious adverse events occurred” at any of the doses tested, with vomiting being the most common side effect and largely confined to higher doses.
Equally important, the kratom administered “did not have detectable 7-HMG [7-OH] levels found in some marketed kratom products”. That single fact underscores the difference between natural kratom leaf and the semi-synthetic extracts being sold in corner stores.
The pharmacological effects observed were mild compared to prescription opioids. Pupillary constriction, a telltale sign of opioid activity, was measured at around two millimeters at the highest dose. Morphine or oxycodone, by comparison, regularly exceed four millimeters under similar conditions.
Perhaps most striking was what kratom did not produce. On measures of “drug liking” and willingness to take the drug again, researchers did not observe the clear, dose-related euphoria that typically signals abuse potential.
Still, the authors were careful not to overstate their findings. The kratom used in the trial “may not be representative of drug effects associated with other kratom-containing products in the marketplace”. It was a warning aimed at the growing flood of products spiked with 7-OH or boosted alkaloid concentrations.
The Health Potential of Kratom
Lost in the noise is a simple possibility: natural kratom, used responsibly, may offer real benefits. In the villages of Thailand and Indonesia, where it has been part of daily life for generations, kratom was not treated as a vice but as a tool—an everyday aid for working people. Farmers chewed fresh leaves while harvesting rice; fishermen brewed tea before long nights on the water.
Modern consumers describe similar effects. Many report relief from chronic pain without relying on prescription opioids. Others note improved mood, less anxiety, and greater resilience to everyday stressors. At lower servings, some experience focus and steady energy—almost a natural alternative to coffee. And within recovery communities, kratom is sometimes used anecdotally to ease symptoms of opioid withdrawal, creating space for people working to break free from dependency.
These benefits do not come from concentrated 7-OH. They arise from the plant’s full spectrum of alkaloids working in concert, each balancing the others. To ignore that nuance is to erase both cultural history and emerging evidence.
The Transparency Gap
Even as kratom enters the mainstream, the industry selling it remains shadowed. In convenience stores you’ll find capsules in unmarked bags; online, labels list one or two alkaloids with no hint of the rest. For clinicians advising patients and consumers trying to choose safely, that opacity isn’t just frustrating—it’s dangerous.
This is the fault line between responsible companies and opportunists. Here, transparency stops being a corporate virtue and becomes a public-health necessity.
The Example of Radical Transparency
A handful of companies are setting a higher bar, embracing a “Hide Nothing, Gain Everything” philosophy: show every test, disclose every alkaloid, and publish sourcing so consumers know exactly what they’re using.
Ryan Niddel, CEO of Diversified Botanics, a prominent voice for honesty in the kratom space, has championed this philosophy since entering the market . He argues that trust is earned through disclosure, not marketing, and has pushed for regulation of synthetic 7-OH—warning that chemically manipulated products carry risks natural kratom does not.
It isn’t a frictionless path. By demanding oversight of 7-OH while defending the distinction of natural kratom, Niddel walks a line few leaders’ attempt. In an industry long shaped by opacity, exposing every result and inviting scrutiny is itself an act of courage.
Why Don’t More Companies Show the Data?
The obvious question is why more companies aren’t doing the same. Laboratory testing is available, transparency is achievable—yet most of the industry stays quiet.
Part of the reason is economics: testing every batch, profiling each alkaloid, and disclosing every result is expensive. Part of it is culture: the supplement industry has long operated in gray zones—“proprietary blends,” vague labels. And part of it is fear: opening the books invites accountability, so in the short term it feels safer to reveal as little as possible.
But safer for whom? Not for consumers. Not for clinicians trying to advise patients responsibly. And not for an industry that will ultimately be judged by its lowest common denominator.
The Stakes for Healthcare
This matters beyond consumer confidence; it matters for healthcare. Physicians cannot responsibly advise patients when products on the shelf are inconsistent, mislabeled, or altered. Researchers cannot conduct reliable studies if samples are tainted with synthetic 7-OH. Regulators cannot draw fair lines when the industry fails to distinguish itself.
Transparency, then, is not merely an industry choice, it is a healthcare obligation. Without it, kratom remains a foggy issue, caught between anecdote and alarmism. With it, kratom can be studied, understood, and perhaps even integrated into legitimate therapeutic conversations.
The Final Question
The kratom debate won’t be settled tomorrow. But the way forward is clear: natural kratom and synthetic 7-OH are not the same. One may offer benefits when used responsibly; the other is a manufactured shortcut that magnifies risk. What matters now is honesty—and honesty takes courage.
Some companies have shown that courage. They prove you can hide nothing and gain everything. Their brands are trusted not because they boast superiority, but because they invite scrutiny.
So, if transparency is possible—and the science already shows a difference—one question remains for the rest of the industry: if one company can hide nothing and gain everything, why can’t they?
